PDF(Pubmed)
Abstract：
According to recent reports, ovarian serous borderline tumor (SBT) harboring the BRAF V600E mutation is associated with a lower risk of progression to low-grade serous carcinoma. Preliminary observations suggest that there may be an association between eosinophilic cells (ECs) and the above-mentioned mutation, so this study aimed to evaluate interobserver reproducibility for assessing ECs. Forty-two samples of SBTs were analyzed for ECs with abundant eosinophilic cytoplasm. Immunohistochemical staining and genetic pro-filing were performed in all cases to verify the BRAF V600E mutation. A BRAF V600E mutation was found in 19 of 42 (45%) cases. Inter-observer reproducibility in the assessment of ECs was substantial (κ = 0.7). The sensitivity and specificity for predicting the mutation were 79% and 91%, respectively. Patients with BRAF-mutated SBTs were significantly younger than those without mutation (p = 0.005). SBTs with BRAF mutation were less likely to be accompanied by non-invasive implants than wild-type SBT: 12% (2/17) versus 33% (6/18). Seven cases were excluded due to incomplete cytoreductive surgery. Nevertheless, Fisher\'s exact test showed no significant differences between the two groups (p = 0.228). Overall, this study strengthens the idea that ECs in ovarian SBTs may represent a mutation with prognostic significance, which can serve as a primary screening test for BRAF V600E mutation in this pathologic entity.
摘要：
根据最近的报道，携带BRAFV600E突变的卵巢浆液性交界性肿瘤(SBT)与进展为低级别浆液性癌的风险较低相关.初步观察表明，嗜酸性粒细胞（ECs）与上述突变之间可能存在关联，因此，本研究旨在评估评估ECs的观察者间可重复性。分析了42个SBT样品中具有丰富嗜酸性粒细胞胞浆的ECs。在所有病例中进行免疫组织化学染色和遗传分析以验证BRAFV600E突变。在42例中的19例（45％）中发现了BRAFV600E突变。在ECs评估中，观察者间的可重复性很高（κ=0.7）。预测突变的敏感性和特异性分别为79%和91%,分别。BRAF突变的SBT患者比无突变的患者明显年轻（p=0.005）。与野生型SBT相比,具有BRAF突变的SBT不太可能伴随非侵入性植入物:12%(2/17)对33%(6/18)。由于不完全的细胞减灭术而排除了7例。然而，Fisher精确检验显示两组间无显著性差异(p=0.228)。总的来说,这项研究加强了这样一种观点，即卵巢SBT中的ECs可能代表一种具有预后意义的突变，它可以作为该病理实体中BRAFV600E突变的初步筛选测试。
